Browse > Article
http://dx.doi.org/10.4014/jmb.2110.10039

RK-270D and E, Oxindole Derivatives from Streptomyces sp. with Anti-Angiogenic Activity  

Jang, Jun-Pil (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Jang, Mina (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Nogawa, Toshihiko (RIKEN Center for Sustainable Research Science)
Takahashi, Shunji (Natural Products Biosynthesis Research Unit and RIKEN-KRIBB Joint Research Unit, RIKEN Center for Sustainable Research Science)
Osada, Hiroyuki (RIKEN Center for Sustainable Research Science)
Ahn, Jong Seog (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Ko, Sung-Kyun (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Jang, Jae-Hyuk (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Publication Information
Journal of Microbiology and Biotechnology / v.32, no.3, 2022 , pp. 302-306 More about this Journal
Abstract
A chemical investigation of a culture extract from Streptomyces sp. RK85-270 led to the isolation and characterization of two new oxindoles, RK-270D (1) and E (2). The structures of 1 and 2 were determined by analyzing spectroscopic and spectrometric data from 1D and 2D NMR and High-resolution electrospray ionization mass spectrometry (HRESIMS) experiments. Compound 1 exhibited anti-angiogenic activities against human umbilical vein endothelial cells (HUVECs) without cytotoxicity. Results of Western blot analysis revealed that 1 inhibits VEGF-induced angiogenesis in the HUVECs via VEGFR2/ p38 MAPK-mediated pathway.
Keywords
Oxindole; Streptomyces sp.; structural elucidation; anti-angiogenic activity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kim GS, Jang J-P, Kwon M, Oh TH, Heo KT, Lee B, et al. 2021. Jejucarbazoles A-C, carbazole glycosides with indoleamine 2,3-dioxygenase 1 inhibitory activity from Streptomyces sp. KCB15JA151. RSC. Adv. 11: 19805-19812.   DOI
2 Zheng D, Han L, Jiang Y, Cao YR, Liu J, Chen X, et al. 2013. Structure elucidation of four prenylindole derivatives from Streptomyces sp. isolated from Ailuropoda melanoleuca feces. Magn. Reson. Chem. 51: 188-191.   DOI
3 Bryan BA, D'Amore PA. 2007. What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell. Mol. Life. Sci. 64: 2053-2065.   DOI
4 Lee J, Hahm E-R, Singh SV. 2010. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 11: 1991-1998.
5 Newman DJ, Cragg GM. 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83: 770-803.   DOI
6 Saito S, Kato W, Ikeda H, Katsuyama Y, Ohnishi Y, Imoto M. 2020. Discovery of "heat shock metabolites" produced by thermotolerant actinomycetes in high-temperature culture. J. Antibiot. 73: 203-210.   DOI
7 Jang J-P, Nogawa T, Futamura Y, Shimizu T, Hashizume D, Takahashi S, et al. 2017. Octaminomycins A and B, cyclic octadepsipeptides active against Plasmodium falciparum. J. Nat. Prod. 80: 134-140.   DOI
8 Rini BI. 2007. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res. 13: 1098-1106.   DOI
9 Nakae K, Yoshimoto Y, Sawa T, Homma Y, Hamada M, Takeuchi T, et al. 2005. Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. 10: 1130-1136.
10 Jang J-P, Nogawa T, Uramoto M, Okano A, Futamura Y, Shimizu T, et al. 2015. RK-270A-C, new oxindole derivatives isolated from a microbial metabolites fraction library of Streptomyces sp. RK85-270. J. Antibiot. 68: 293-295.   DOI
11 Ng EWM, Adamis AP. 2005. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40: 352-368.   DOI
12 Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell. Biol. 7: 359-371.   DOI
13 Carmeliet P. 2003. Angiogenesis in health and disease. Nat. Med. 6: 653-660.   DOI
14 Fenical W, Jensen PR. 2006. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2: 666-673.   DOI
15 Jang J-P, Hwang GJ, Jang M, Takahashi S, Ko SK, Osada H, et al. 2018. Aturanosides A and B, glycosylated anthraquinones with antiangiogenic activity from a soil-derived Streptomyces species. J. Nat. Prod. 81: 2004-2009.   DOI
16 Jang J-P, Hwang GJ, Kwon MC, Ryoo IJ, Jang M, Takahashi S, et al. 2018. Pentaminomycins A and B, hydroxyarginine-containing cyclic pentapeptides from Streptomyces sp. RK88-1441. J. Nat. Prod. 81: 806-810.   DOI
17 Zhang J, Shen Y, Liu J, Wei, D. 2005. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem. Pharmacol. 3: 407-414.   DOI
18 Lamalice L, Houle F, Jourdan G, Huot J. 2004. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23: 434-445.   DOI